ONI BioPharma Inc. Commences Market Launch of Unique Oral Probiotic Product

  ONI BioPharma Inc. (AMEX: ONI) announced today
that it is commencing the marketing launch of its unique oral care group of
probiotics, known collectively as ProBiora3(TM).  This extraordinary
technology is the result of over 30 years of scientific and clinical
research.  ProBiora3 is an integrated oral care product that contains three
natural, human-derived, oral probiotic bacteria designed to promote healthy
teeth and gums, as well as whiten teeth and freshen breath.

ProBiora3 will be distributed through a wide array of mass marketing channels beginning with a group of products manufactured by and for ONI under the name Evora. The first product, a wholly natural mint flavored lozenge, will be known as EvoraPlus(TM) and will address adult oral health. Following shortly thereafter, the Company will market modified formulations that address the oral health needs of children and the fast-growing companion pet market.

All of the ProBiora3 products will be marketed under the generally recognized as safe (GRAS) provision of the U.S. FDA regulations. One of the elements of GRAS status is that it limits the type of claims that ONI can make with respect to this group. GRAS status goods account for billions of dollars in sales of beneficial products. In sales previews, mass retailers have indicated a desire to purchase the product in substantial quantities for the final quarter of 2008 as well as in larger quantities for the 1st quarter of 2009.

ONI has hired Gerald David, a widely recognized expert in nutraceutical sales, along with other key staff members to manage the sales and marketing of ProBiora3. Mr. David, who will operate out of a new sales office located in Tampa, FL, has planned a television, print media and internet information and sales campaign, which has already begun in the United States. EvoraPlus will be offered on a number of large retail sales sites. ONI is arranging for a credit facility to finance these efforts. Retailers can expect initial deliveries in October.

ONI believes that the ProBiora3 group of products will join other successful probiotics which have long been sold throughout the world, and more recently in the United States. ProBiora3 will be the first probiotic that address all of the major oral health concerns.

The Company's President and CEO, Stanley B. Stein, stated that, "ProBiora3 represents ONI's long-term commitment to commercialize its extraordinary scientific platforms, and I expect that further announcements about new products, projects, initiatives, and realized sales will be forthcoming with regularity."

About ONI BioPharma Inc.

ONI BioPharma Inc. is a biopharmaceutical company with a pipeline of unique proprietary technologies, some of which are being commercialized. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies with respect to its products, thereby creating a pipeline of future products, which the Company expects to develop.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect ONI BioPharma's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact: ONI BioPharma Inc. Stanley B. Stein 386-418-4018 X222 www.oragenics.com